每經記者  劉林鵬  發自成都

    一則不足百字的(de)公告，宣告一家公司的(de)管理(li)架構發生(sheng)重大(da)變化。

    港股(gu)上市(shi)公(gong)司(si)維(wei)奧醫藥控(kong)股(gu)有(you)限(xian)(xian)公(gong)司(si)（01164，HK，以(yi)(yi)下(xia)簡稱維(wei)奧集團）的全資(zi)子公(gong)司(si)———四(si)川維(wei)奧制藥有(you)限(xian)(xian)公(gong)司(si)（以(yi)(yi)下(xia)簡稱四(si)川維(wei)奧制藥）昨日(ri)（5月24日(ri)）發布《分立公(gong)告(gao)》，決定將(jiang)公(gong)司(si)分為四(si)川維(wei)奧制藥有(you)限(xian)(xian)公(gong)司(si)、四(si)川維(wei)奧實業(ye)有(you)限(xian)(xian)公(gong)司(si)兩家公(gong)司(si)。

    昨日(ri)，《每日(ri)經濟新(xin)聞》記(ji)者(zhe)來到位于成(cheng)都高新(xin)區科園南路的(de)3號的(de)維奧(ao)集(ji)團在(zai)成(cheng)都的(de)辦公(gong)點進行探(tan)訪(fang)。

    上(shang)述(shu)公(gong)(gong)(gong)(gong)告稱，根據2011年5月15日(ri)股東會議(yi)，決(jue)定(ding)將本(ben)公(gong)(gong)(gong)(gong)司(si)(si)分立(li)為四(si)川(chuan)維(wei)(wei)奧制藥(yao)有限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)、四(si)川(chuan)維(wei)(wei)奧實(shi)業(ye)有限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)，四(si)川(chuan)維(wei)(wei)奧實(shi)業(ye)有限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)由(you)四(si)川(chuan)維(wei)(wei)奧制藥(yao)有限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)派生分立(li)，四(si)川(chuan)維(wei)(wei)奧制藥(yao)有限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)繼(ji)續(xu)存續(xu)，請相關(guan)債權(quan)債務人資本(ben)公(gong)(gong)(gong)(gong)告之(zhi)日(ri)起45日(ri)內前往本(ben)公(gong)(gong)(gong)(gong)司(si)(si)辦理相關(guan)債權(quan)債務。

    “將(jiang)四(si)(si)川(chuan)維奧(ao)制藥有限(xian)公(gong)(gong)司分立為四(si)(si)川(chuan)維奧(ao)制藥有限(xian)公(gong)(gong)司、四(si)(si)川(chuan)維奧(ao)實(shi)業有限(xian)公(gong)(gong)司主要是(shi)基于理(li)順股權(quan)關系和(he)管理(li)關系的(de)考慮。”維奧(ao)集(ji)團法務部經理(li)陳宗(zong)燕(yan)向記者表(biao)示(shi)，四(si)(si)川(chuan)維奧(ao)實(shi)業有限(xian)公(gong)(gong)司將(jiang)成為一家投(tou)資管理(li)性質的(de)公(gong)(gong)司，四(si)(si)川(chuan)維奧(ao)制藥將(jiang)集(ji)中于精力從事(shi)醫藥的(de)生產。

    “此次(ci)分立對(dui)四川維奧的債權(quan)人不(bu)會(hui)有什(shen)么影響。”陳宗燕(yan)稱(cheng)。

如需轉載請與《每日經濟新聞》報社聯系。未經《每日經濟新聞》報社授權，嚴禁轉載或鏡像，違者必究。

聯系電話：021-60900099轉688

每經訂報電話

北京：010-58528501    上海：021-61283003    深圳：0755-83520159    成都：028-86516389    028-86740011    無錫：15152247316    廣州：020-89660257